This is a routine, small-dollar insider sale by a director under a 10b5-1 plan. No material signal for the stock. Monitor for any acceleration of insider selling or changes in the 10b5-1 plan, but this filing alone does not warrant a trading response.
Price Chart
Executive Summary
Director Leonard Post filed a Form 144 notice of intent to sell 5,000 shares of CG Oncology common stock, with an estimated aggregate market value of $328,650. The shares are to be acquired through the exercise of stock options, and the sale is planned under a Rule 10b5-1 trading plan. This is a routine insider sale by a director, not a top executive, and the dollar amount is small relative to the company's $6.1B market cap.
Key Facts
- Director Leonard Post filed Form 144 on June 24, 2026, indicating intent to sell 5,000 shares.
- Estimated aggregate market value of the proposed sale is $328,650.
- Shares are to be acquired upon exercise of stock options; sale is part of a pre-arranged 10b5-1 plan.
- The sale represents a tiny fraction of the company's $6.1B market cap.
- Prior 30-day insider activity includes 3 sells totaling $419K, consistent with routine option exercise/sale patterns.
Financial Impact
Proposed sale of 5,000 shares valued at ~$328,650, representing less than 0.01% of market cap.
Risk Factors
- Insider selling could accelerate if the 10b5-1 plan is expanded or if other insiders follow suit.
- The company's historical T+20 win rate on prior reports is only 44%, suggesting limited predictive power from this filing type.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-006467 |
| Document: 0001950047-26-006467-index.html | 0001950047-26-006467 |
| Document: 0001950047-26-006467.txt | 0001950047-26-006467 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Press Release | $74.85 $74.33 | ▲ +0.69% | ▲ +1.29% | $67.38 (+9.98%) |
Aug 6, 2026 8w ago | 424B5 | $74.85 $74.33 | ▲ +0.69% | ▲ +1.29% | $67.38 (+9.98%) |
Jul 27, 2026 9w ago | Press Release | $72.62 $78.95 | ▲ +8.72% | ▲ +5.34% | $67.38 (−7.22%) |
Jul 17, 2026 11w ago | Insider Cluster | $71.85 $75.03 | ▲ +4.43% | ▼ −0.02% | $67.38 (−6.22%) |
Jul 16, 2026 11w ago | Court Ruling | $69.50 $74.71 | ▲ +7.50% | ▲ +3.88% | $67.38 (−3.05%) |
Jun 24, 2026 14w ago | 144 | $72.84 $71.12 | ▼ −2.36% | ▼ −2.89% | $67.38 (−7.50%) |
Jun 22, 2026 14w ago | 144 | $65.73 $70.19 | ▲ +6.79% | ▲ +5.63% | $67.38 (+2.51%) |
Jun 12, 2026 16w ago | Institutional Cluster | $59.56 $75.24 | ▲ +26.33% | ▲ +24.55% | $67.38 (+13.13%) |
May 26, 2026 18w ago | 8-K | $61.89 $70.25 | ▲ +13.50% | ▲ +15.45% | $67.38 (+8.87%) |
May 15, 2026 20w ago | Press Release | $66.93 $59.56 | ▼ −11.01% | ▼ −13.13% | $67.38 (+0.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access